Clinical Trial Update: Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating linsitinib in asymptomatic or mildly symptomatic metastatic prostate cancer has completed enrollment and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Linsitinib (linsitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-03-13